ES2631655T3 - Procedimiento para fabricar compuestos de isoquinolina - Google Patents

Procedimiento para fabricar compuestos de isoquinolina Download PDF

Info

Publication number
ES2631655T3
ES2631655T3 ES13740184.0T ES13740184T ES2631655T3 ES 2631655 T3 ES2631655 T3 ES 2631655T3 ES 13740184 T ES13740184 T ES 13740184T ES 2631655 T3 ES2631655 T3 ES 2631655T3
Authority
ES
Spain
Prior art keywords
substituted
aryl
alkyl
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13740184.0T
Other languages
English (en)
Spanish (es)
Inventor
Michael D. Thompson
Jung Min Park
Michael P. Arend
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of ES2631655T3 publication Critical patent/ES2631655T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES13740184.0T 2012-07-16 2013-07-15 Procedimiento para fabricar compuestos de isoquinolina Active ES2631655T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672191P 2012-07-16 2012-07-16
US201261672191P 2012-07-16
PCT/US2013/050538 WO2014014834A1 (en) 2012-07-16 2013-07-15 Process for making isoquinoline compounds

Publications (1)

Publication Number Publication Date
ES2631655T3 true ES2631655T3 (es) 2017-09-01

Family

ID=48857024

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13740184.0T Active ES2631655T3 (es) 2012-07-16 2013-07-15 Procedimiento para fabricar compuestos de isoquinolina

Country Status (22)

Country Link
US (2) US9340511B2 (OSRAM)
EP (2) EP3219706A1 (OSRAM)
JP (1) JP6196671B2 (OSRAM)
KR (1) KR102145272B1 (OSRAM)
CN (2) CN106083719B (OSRAM)
AU (1) AU2013290437B2 (OSRAM)
BR (1) BR112015001106B1 (OSRAM)
CA (1) CA2879238C (OSRAM)
CY (1) CY2022018I1 (OSRAM)
DK (1) DK2872487T3 (OSRAM)
ES (1) ES2631655T3 (OSRAM)
HU (2) HUE034409T2 (OSRAM)
IL (1) IL236625B (OSRAM)
IN (1) IN2015KN00265A (OSRAM)
MX (1) MX350922B (OSRAM)
MY (1) MY171483A (OSRAM)
NZ (1) NZ704660A (OSRAM)
PL (1) PL2872487T3 (OSRAM)
PT (1) PT2872487T (OSRAM)
SG (1) SG11201500234YA (OSRAM)
WO (1) WO2014014834A1 (OSRAM)
ZA (1) ZA201500664B (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
CN109369524A (zh) * 2012-07-16 2019-02-22 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
HUE034409T2 (en) * 2012-07-16 2018-02-28 Fibrogen Inc Process for the preparation of isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
CN105377242A (zh) 2013-06-06 2016-03-02 菲布罗根有限公司 Hif羟化酶抑制剂的药物制剂
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
CN105384687B (zh) 2014-09-02 2018-05-01 广东东阳光药业有限公司 喹啉酮类化合物及其在药物中应用
WO2016045125A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CN104447547B (zh) * 2014-11-10 2017-04-19 苏州康润医药有限公司 4‑氨基异喹啉‑8‑甲酸甲酯的合成方法
CN106146490B (zh) * 2015-03-27 2018-10-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN106478503A (zh) * 2016-09-29 2017-03-08 上海勋和医药科技有限公司 Roxadustat中间体的制备方法
CZ2016627A3 (cs) 2016-10-07 2018-04-18 Zentiva, K.S. Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu
CN107954931B (zh) * 2016-10-17 2021-06-22 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
EP3573615B1 (en) * 2017-01-28 2024-06-12 Kingchem Life Science LLC A process for preparing 5-phenoxy-1(3h)isobenzofuranone
US20200299242A1 (en) * 2017-12-01 2020-09-24 Dr. Reddy's Laboratories Limited Process for the preparation of roxadustat and its intermediates
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
CN110218184B (zh) * 2018-03-01 2022-09-27 广东东阳光药业有限公司 诺德司他共晶及其制备方法
WO2019174631A1 (zh) * 2018-03-16 2019-09-19 上海医药集团股份有限公司 一种诺得司他的制备方法
CN110526813B (zh) * 2018-05-24 2022-06-28 杭州科巢生物科技有限公司 异喹啉化合物的制备方法及其中间体
WO2019233321A1 (zh) 2018-06-05 2019-12-12 沈阳化工大学 一种三氟乙基硫醚(亚砜)取代苯类化合物及其用途
AU2019375983A1 (en) 2018-11-09 2021-06-10 Vivace Therapeutics, Inc. Bicyclic compounds
CN109776415B (zh) * 2019-03-07 2020-11-17 福建南方制药股份有限公司 一种Roxadustat中间体的制备方法
EP3956033B1 (en) 2019-04-16 2024-12-11 Vivace Therapeutics, Inc. Bicyclic compounds
RU2709493C1 (ru) * 2019-08-01 2019-12-18 Марат Феликсович Фазылов Способ получения роксадустата
US20220340532A1 (en) 2019-08-07 2022-10-27 Teva Pharmaceuticals International Gmbh Processes for the preparation of roxadustat and intermediates thereof
CN112441975B (zh) * 2019-09-03 2023-10-31 西藏嘉信景天药业有限公司 一种罗沙司他重要中间体的制备方法
US20230112619A1 (en) * 2019-10-18 2023-04-13 Shanghai Desano Chemical Pharmaceutical Co., Ltd. Method for preparing isoquinolinone compounds
CN112679430B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN112679431B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN113444042A (zh) * 2020-03-27 2021-09-28 南京海润医药有限公司 一种罗沙司他的制备方法
WO2021214785A1 (en) 2020-04-21 2021-10-28 Mylan Laboratories Limited Improved process for the preparation of roxadustat
CN111533691A (zh) * 2020-06-08 2020-08-14 重庆三圣实业股份有限公司 一种罗沙司他的制备方法
CN113801060B (zh) * 2020-06-13 2025-06-27 苏州鹏旭医药科技有限公司 一种多取代异喹啉化合物的制备方法
EP4169906B1 (en) * 2020-06-19 2024-09-04 Jumpcan (Shanghai) Medical Technology Co., Ltd Method for synthesis of roxadustat and intermediate thereof, and intermediate thereof
CN112409258B (zh) * 2020-11-20 2025-11-25 杭州科巢生物科技有限公司 一种罗沙司他的制备方法
CN114644589A (zh) * 2020-12-17 2022-06-21 鲁南制药集团股份有限公司 一种化合物n-[（4-羟基--1-甲基-3-异喹啉基）羰基]-甘氨酸的制备方法
CN114671807A (zh) * 2020-12-24 2022-06-28 联化科技（德州）有限公司 一种1-取代异喹啉类化合物的制备方法
US20230101768A1 (en) * 2021-08-13 2023-03-30 The Board Of Regents Of The University Of Texas System Method to treat manganese toxicity and manganese-induced parkinsonism in humans
CN116178260A (zh) * 2021-11-26 2023-05-30 四川国康药业有限公司 一种治疗肾性贫血的化合物及其制备方法
CN115124467A (zh) * 2022-07-11 2022-09-30 天津力生制药股份有限公司 一种罗沙司他关键中间体的制备方法
CN117486797A (zh) * 2023-11-23 2024-02-02 传健生物医药(厦门)有限公司 一种罗沙司他关键中间体及罗沙司他的制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
DK0650961T3 (da) 1993-11-02 1997-09-15 Hoechst Ag Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
ES2101420T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
AU5362998A (en) 1996-11-27 1998-06-22 Du Pont Pharmaceuticals Company Novel integrin receptor antagonists
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
JP2005505507A (ja) 2001-06-13 2005-02-24 ジーンソフト ファーマシューティカルズ インコーポレイテッド 抗感染活性を有するイソキノリン化合物
AU2002312371A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Aryl-benzimidazole compounds having antiinfective activity
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
ES2414706T3 (es) 2001-12-06 2013-07-22 Fibrogen, Inc. Métodos para aumentar la eritropoyetina endógena
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
CN100418948C (zh) 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
ATE443775T1 (de) 2004-05-28 2009-10-15 Fibrogen Inc Hif-prolylhydroxylase-aktivitätstest
AP2007004047A0 (en) * 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
ATE513833T1 (de) 2005-03-02 2011-07-15 Fibrogen Inc Thienopyridinverbindungen und verfahren zu ihrer verwendung
EP1893186A2 (en) 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
DE602006014843D1 (de) 2005-06-15 2010-07-22 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
US7660807B2 (en) 2005-11-28 2010-02-09 Commvault Systems, Inc. Systems and methods for cataloging metadata for a metabase
DK2044028T3 (da) 2006-01-27 2012-08-20 Fibrogen Inc Cyanoisoquinolinforbindelser til stabilisering af den hypoxiinducerende faktor (HIF)
WO2007097929A1 (en) 2006-02-16 2007-08-30 Fibrogen, Inc. Compounds and methods for treatment of stroke
BRPI0710527B8 (pt) 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
WO2010022240A1 (en) 2008-08-20 2010-02-25 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
CN103429239A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加网织红细胞血红蛋白含量的方法
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
WO2013013609A1 (en) 2011-07-22 2013-01-31 Zhejiang Beta Pharma Incorporation Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
SG11201405574UA (en) 2012-03-09 2014-10-30 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
HUE034409T2 (en) 2012-07-16 2018-02-28 Fibrogen Inc Process for the preparation of isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
CN109369524A (zh) 2012-07-16 2019-02-22 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
EP2951159B1 (en) 2013-01-24 2018-08-22 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
CN105377242A (zh) 2013-06-06 2016-03-02 菲布罗根有限公司 Hif羟化酶抑制剂的药物制剂

Also Published As

Publication number Publication date
ZA201500664B (en) 2017-08-30
MX350922B (es) 2017-09-25
US9708269B2 (en) 2017-07-18
WO2014014834A1 (en) 2014-01-23
CA2879238A1 (en) 2014-01-23
US20160194285A1 (en) 2016-07-07
CA2879238C (en) 2021-08-10
BR112015001106B1 (pt) 2021-11-09
DK2872487T3 (en) 2017-06-06
CY2022018I2 (el) 2023-01-05
MY171483A (en) 2019-10-15
HUS2200030I1 (hu) 2022-07-28
EP2872487A1 (en) 2015-05-20
CY2022018I1 (el) 2023-01-05
EP2872487B1 (en) 2017-04-26
CN106083719A (zh) 2016-11-09
JP6196671B2 (ja) 2017-09-13
HUE034409T2 (en) 2018-02-28
US9340511B2 (en) 2016-05-17
AU2013290437B2 (en) 2017-11-02
KR20150058147A (ko) 2015-05-28
SG11201500234YA (en) 2015-02-27
CN106083719B (zh) 2019-10-18
PL2872487T3 (pl) 2017-09-29
CN103435546A (zh) 2013-12-11
JP2015524409A (ja) 2015-08-24
AU2013290437A1 (en) 2015-02-19
US20150175550A1 (en) 2015-06-25
EP3219706A1 (en) 2017-09-20
IL236625B (en) 2019-01-31
IL236625A0 (en) 2015-02-26
KR102145272B1 (ko) 2020-08-18
CN103435546B (zh) 2016-08-10
PT2872487T (pt) 2017-05-15
BR112015001106A2 (pt) 2017-06-27
MX2015000505A (es) 2015-07-17
IN2015KN00265A (OSRAM) 2015-06-12
NZ704660A (en) 2017-10-27

Similar Documents

Publication Publication Date Title
ES2631655T3 (es) Procedimiento para fabricar compuestos de isoquinolina
ES2390004T3 (es) Derivados sustituidos de piperidina espirocíclica como ligandos del receptor de la histamina 3(H3)
ES2945220T3 (es) Indazol carboxamidas como inhibidores de cinasas
KR20230149873A (ko) Ｃ5ａＲ 길항제의 제조 방법 및 이러한 제조에서의 중간체
CA2470620A1 (en) Compounds for the treatment of inflammatory disorders
ES2830266T3 (es) Compuestos intermedios para la preparación de sacubitril y su preparación
KR20180117627A (ko) 치료 화합물
TWI679204B (zh) 苯并惡唑并惡嗪酮類化合物的製備方法及其中間體和晶型
WO2023034346A1 (en) Chromen-2-one modulators of polrmt
KR102593509B1 (ko) 질소 머스타드 유도체의 제조 방법
CN103396351A (zh) 吡咯烷类Bcl-2蛋白小分子抑制剂化合物及其制备、药物组合物与制药用途
CN108137505A (zh) 含氮杂环化合物
HK1231055B (zh) 制备异喹啉化合物的方法
CN108689904B (zh) 手性杂环叔醇中间体的制备方法及其应用
HK1231055A1 (en) Process for making isoquinoline compounds
JP2013544787A (ja) アザインダゾール誘導体の調製方法
Wang et al. Synthesis and bioactivity of N-[5-(2-chlorophenyl)-2-furamidothiocarbonyl]-L-α-amino acid ethyl esters
BR102015005344A2 (pt) processo e intermediários para a preparação de dasatinib
Marcaccini et al. Synthesis of diverse phenylglycine derivatives via transformation of Ugi four-component condensation primary adducts
WO2007088878A1 (ja) ベンゾアゼピノン類の製造方法
CN117659011A (zh) 一种合成阿哌沙班的新方法
Guo et al. Synthesis and Anti‐tumor Activities of Novel Methylthio‐, Sulfinyl‐, and Sulfonyl‐8H‐thieno [2, 3‐b] pyrrolizin‐8‐oximino Derivatives
CN108136213A (zh) 塞拉集宁的合成方法
CA2673233A1 (en) Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
TW202039430A (zh) 製備磺胺類藥物的方法